论文部分内容阅读
癌胚抗原（CEA）由Gold等于1965年首次报告后，国外相继对抗原成分、特异性、临床应用及其对肿瘤诊断的价值，进行了深入的研究和评价。认为目前CEA 作为肿瘤标志物，虽然特异性不够高、尚难早期诊断肿瘤，但对于直（结）肠癌监测术后疗效、复发、预后等，其价值是公认的。Munjal等认为CEA结合己醣异构酶（PHI）对肿瘤的旺转移，是较好的标志，酶和CEA同时升高，其水平可提示癌扩散的广度。国内对CEA诊断肺癌的研究亦有报道。我们使用北京生物制品研究所的CEA—EIA试药盒，检测了正常人54例，临床病人216例，对CEA临床价值作初步探讨。
Carcinoembryonic antigen (CEA) was first reported by Gold et al. in 1965. It has conducted in-depth research and evaluation on the antigen composition, specificity, clinical application and its value in tumor diagnosis. It is believed that the current CEA as a tumor marker has low specificity and it is difficult to diagnose tumors early. However, its value for postoperative curative effect, recurrence, and prognosis of rectal cancer is well recognized. Munjal et al. believe that CEA combined with hexose isomerase (PHI) is a good marker for metastasis of tumors. Enzymes and CEA are elevated at the same time, and their levels may indicate the extent of cancer spread. Domestic studies on the diagnosis of lung cancer by CEA have also been reported. We used the CEA-EIA test kit of the Beijing Institute of Biological Products to detect 54 cases of normal persons and 216 cases of clinical patients. We conducted a preliminary study on the clinical value of CEA.